Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.
Orelabrutinib offers chronic lymphocytic leukemia patients a gentler first-line treatment option with stronger disease control than older chemotherapy approaches.
This randomized phase 3 trial (NCT04578613) enrolled 192 treatment-naïve CLL/SLL patients and compared orelabrutinib (n=91) to chlorambucil plus rituximab (n=101) at a median follow-up of 21.4 months. Orelabrutinib achieved superior progression-free survival (HR 0.32) and a higher response rate with a significantly better safety profile, establishing it as an effective first-line BTK inhibitor alternative.
What the study was
- Study design
- randomized_controlled_trial
- Category
- hematological oncology
- Maturity
- Potentially Practice-Changing
- Journal
- Signal Transduction and Targeted Therapy
Why it surfaced
Phase 3 multicenter RCT comparing next-generation BTK inhibitor orelabrutinib to standard chemoimmunotherapy in first-line CLL/SLL with statistically significant primary endpoint. Published in STTT (IF ~40+). Directly impacts standard-of-care for one of the most common adult B-cell malignancies.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.